uniQure stock jumps as FDA accepts Huntington’s therapy filing
Summary
Shares of uniQure experienced a significant increase following the regulatory acceptance of its therapeutic application for Huntington's disease. The United States Food and Drug Administration agreed to review the filing submitted by the biotechnology company.
Source: Read the full story at Stock Market News
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.